Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials

Abstract Introduction Deucravacitinib, a novel, oral, selective allosteric tyrosine kinase 2 inhibitor, demonstrated superiority versus placebo and apremilast in the POETYK PSO-1 and PSO-2 studies. We describe patient-reported outcomes with deucravacitinib treatment versus placebo and apremilast in...

Descripció completa

Dades bibliogràfiques

Autors principals:	April W. Armstrong, Matthias Augustin, Jennifer L. Beaumont, Tan P. Pham, Stacie Hudgens, Kenneth B. Gordon, Joe Zhuo, Brandon Becker, Yichen Zhong, Renata M. Kisa, Subhashis Banerjee, Kim A. Papp
Format:	Artigo
Idioma:	Inglês
Publicat:	Adis, Springer Healthcare 2024-07-01
Col·lecció:	Dermatology and Therapy
Matèries:	Clinical trial Minimum clinically important difference Psoriasis Quality of life Treatment efficacy
Accés en línia:	https://doi.org/10.1007/s13555-024-01224-x
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!